Edick R. Paul's Insider Trades & SAST Disclosures
Edick R. Paul's most recent trade in Xeris Biopharma Holdings Inc was a trade of 1,500,000 Common Stock done . Disclosure was reported to the exchange on Jan. 31, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Edick R. Paul.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc | R. Edick Paul | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 1,500,000 | 3,788,064 (13%) | 5% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | Edick R. Paul | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 500,000 | 500,000 | - | - | Stock Appreciation Right | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 2.38 per share. | 09 Aug 2023 | 10,000 | 2,288,064 (8%) | 0% | 2.4 | 23,794 | Common Stock |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 750,000 | 2,278,064 (8%) | 2% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 1.45 per share. | 13 Dec 2022 | 20,000 | 1,528,064 (5%) | 0% | 1.5 | 29,000 | Common Stock |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 1.40 per share. | 12 May 2022 | 100,000 | 1,508,064 (5%) | 0% | 1.4 | 140,380 | Common Stock |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 600,000 | 1,408,064 (5%) | 2% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 15 Nov 2021 | 20,000 | 33,430 (0%) | 0% | 2.3 | 45,664 | Common Stock |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 2.08 per share. | 11 Nov 2021 | 200,000 | 808,064 (2%) | 0% | 2.1 | 415,760 | Common Stock |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 668,065 | 668,065 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 668,065 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 410,833 | 608,064 (2%) | 1% | - | Common Stock | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 410,833 | 0 (0%) | 1% | - | Common Stock | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 400,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 200,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 197,231 | 197,231 (0%) | 0% | - | Common Stock | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 197,231 | 410,833 (1%) | 0% | - | Common Stock | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 98,252 | 98,252 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 98,252 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 69,822 | 69,822 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 69,822 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 13,430 | 0 (0%) | 0% | - | Common Stock | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 13,430 | 13,430 (0%) | 0% | - | Common Stock | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 225,000 | 636,134 (2%) | 0% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | Paul R. Edick | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 4.06 per share. | 09 Dec 2020 | 10,000 | 411,134 (1%) | 0% | 4.1 | 40,551 | Common Stock |
| Milestone Pharmaceuticals Inc | Paul R. Edick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges